New weight loss drug, the world’s first cAMP-biased GLP-1 agonist has been submitted for marketing
December 21, 2024
Source: drugdu
35
On December 16, Xinweida Bio announced that the company's application for marketing authorization for the new indication of the Class 1 new drug Ecnoglutide Injection was accepted by the CDE for long-term weight management of adult patients on the basis of controlling diet and increasing physical activity.
Ecnoglutide Injection is the world's first new long-acting GLP-1 agonist with cAMP bias independently developed by Xinweida Bio. Its three China Phase III registered clinical studies on adult type 2 diabetes and obesity have been successfully completed, and some results have been published at the American Diabetes Congress and the European Diabetes Congress. The completed clinical data confirmed that Ecnoglutide Injection has excellent therapeutic effects on patients with type 2 diabetes and obesity, and shows good safety and tolerability.
In November this year, the indication of Ecnoglutide for blood sugar control in adult patients with type 2 diabetes has been submitted for marketing.
https://mp.weixin.qq.com/
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Yingtai Medical acquires Weiqiang Medical December 21, 2024
- 4 innovative medical devices approved for market launch December 21, 2024
- Once a month, potential “best-in-class” lipid-lowering drugs apply for listing December 21, 2024
- Notice! Xinma Pharmaceutical Recruitment and Procurement Involved in Bribery December 21, 2024
- The president of a century-old Chinese medicine hospital was investigated and was boycotted for his identity as a Western medicine doctor December 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
